A new level of collaboration is needed to overcome the current and future challenges facing healthcare globally, according to international research presented recently.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh